Vitreomacular adhesion treatment under EMA review

Article

It has been announced that the European Medicines Agency (EMA) is currently reviewing Ocriplasmin as the first pharmacological treatment for vitreomacular adhesion (VMA).

It has been announced that the European Medicines Agency (EMA) is currently reviewing Ocriplasmin as the first pharmacological treatment for vitreomacular adhesion (VMA).

The treatment, developed by ThromboGenics, has successfully completed two Phase III clinical trials for VMA - including macular hole. It is delivered via intravitrieal injection and targets the fibronectin, laminin and type IV collagen fibres that are attached to the vitreous. European availability of ocriplasmin could enable retinal specialists to treat patients earlier, compared to surgery.

Alcon has planned to collaborate with ThromboGenics to commercialize ocriplasmin in over 40 countries, including those in Europe. The firm will initially invest €75 million into ThromboGenics’s strategic role in marketing ocriplasmin to the US, whereas Alcon will focus on European commercialization.

Dr Patrik De Haes, CEO of ThromboGenics, said, “We are pleased that Alcon has recognized the potential of ocriplasmin to change the way symptomatic VMA including macular hole is treated. Alcon is the ideal partner for an innovative retinal therapy given its global sales, marketing and medical capabilities in the ophthalmic market and its commitment to making ocriplasmin a success.”

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.